Wadelai, an isolated focus for onchocerciasis in northwest Uganda, was selected for piloting an onchocerciasis elimination strategy that was ultimately the precursor for countrywide onchocerciasis elimination policy. The Wadelai focus strategy was to increase ivermectin treatments from annual to semiannual frequency and expand geographic area in order to include communities with nodule rate of less than 20%. These communities had not been covered by the previous policy that sought to control onchocerciasis only as a public health problem. From 2006 to 2010, Wadelai program successfully attained ultimate treatment goal (UTG), treatment coverage of ≥90%, despite expanding from 19 to 34 communities and from 5,600 annual treatments to over 29,000 semiannual treatments. Evaluations in 2009 showed no microfilaria in skin snips of over 500 persons examined, and only 1 of 3011 children was IgG4 antibody positive to the OV16 recombinant antigen. No Simulium vectors were found, and their disappearance could have sped up interruption of transmission. Although twice-per-year treatment had an unclear role in interruption of transmission, the experience demonstrated that twice-per-year treatment is feasible in the Ugandan setting. The monitoring data support the conclusion that onchocerciasis has been eliminated from the Wadelai focus of Uganda. 1. Introduction The Wadelai onchocerciasis focus is one of the smallest in Uganda, comprising only about 15,000 people living close to the lower River Ora in the Nebbi district. It is not clear when this focus first came to the attention of the health authorities, but in 1951 onchocerciasis was recognised in the upper reaches of the River Aroga (a major tributary of the River Ora). The vector was assumed to be Simulium neavei [1] based on the forested environment. Much more was learnt of the distribution of onchocerciasis and its vectors in the following two decades. The breeding of a non-man-biting form of S. damnosum s.l, was reported in 1966 along River Ali, located opposite Rhino Camp roughly 15 kilometres downstream of the River Ora outfall [2, 3]. Barnley in his lecture notes delivered at Makerere University in 1968 entitled “The Distribution of Onchocerciasis and its Vectors in Uganda”, confirmed that S. neavei was the vector in the upper reaches of River Ora system, but made no mention of the situation in its lower reaches where the Wadelai focus is located [4]. Later in the Uganda Atlas of disease distribution, Barnley gave a distribution map of onchocerciasis and its vectors showing the presence of a small
References
[1]
G. S. Nelson, “Onchocerciasis in the West Nile district of Uganda,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 52, no. 4, pp. 368–376, 1958.
[2]
A. W. R. McCrae, “The Simulium damnosum species complex,” East African Virus Research Institute Report, vol. 16, pp. 38–39, 1967.
[3]
A. W. R. McCrae, “The Simulium damnosum species complex,” East African Virus Research Institute Report, vol. 17, pp. 67–70, 1968.
[4]
G. R. Barnley, “The Distribution of Onchocerciasis and its vectors,” Unpublished Lecture Notes, Makerere University, 1968.
[5]
S. A. Hall and B. W. Langlands, Onchocerciasis in Uganda in Uganda Atlas of Disease Distribution, East African Publishing House, 1975.
[6]
WHO Report, “Methods for community diagnosis of onchocerciasis to guide ivermectin-based control in Africa,” Tech. Rep. TDR/TDR/ONCHO/92.2, World Health Organization, Geneva, Switzerland, 1991.
[7]
P. Ngoumou, J. F. Walsh, and J. M. Mace, “A rapid mapping technique for the prevalence and distribution of onchocerciasis: a Cameroon case study,” Annals of Tropical Medicine and Parasitology, vol. 88, no. 5, pp. 463–474, 1994.
[8]
M. Katabarwa, A. W. Onapa, and B. Nakileza, “Rapid epidemiological mapping of onchocerciasis in areas of Uganda where Simulium Neavei SL is the vector,” East African Medical Journal, vol. 76, no. 8, pp. 440–446, 1999.
[9]
H. Schulz Key, “A simple technique to assess the total number of Onchocerca volvulus microfilariae in skin snips,” Tropenmedizin und Parasitologie, vol. 29, no. 1, pp. 51–54, 1978.
[10]
WHO Report, “Community Directed Treatment with Ivermectin,” Document TDR/AFR/Selection and Validation of Indicators for Monitoring RP/96.1, Geneva, Switzerland, 1996.
[11]
M. Noma, B. E. B. Nwoke, I. Nutall et al., “Rapid epidemiological mapping of onchocerciasis (REMO): its application by the African Programme for Onchocerciasis Control (APOC),” Annals of Tropical Medicine and Parasitology, vol. 96, supplement 1, pp. S29–S39, 2002.
[12]
M. N. Katabarwa, A. Eyamba, M. Chouaibou et al., “Does onchocerciasis transmission take place in hypoendemic areas? A study from the North Region of Cameroon,” Tropical Medicine and International Health, vol. 15, no. 5, pp. 645–652, 2010.
[13]
F. O. Richards Jr., E. S. Miri, M. Katabarwa et al., “The Carter Center's assistance to river blindness control programs: establishing treatment objectives and goals for monitoring ivermectin delivery systems on two continents,” American Journal of Tropical Medicine and Hygiene, vol. 65, no. 2, pp. 108–114, 2001.
[14]
B. O. L. Duke, A. M. Marty, D. L. Peet et al., “Neoplastic change in Onchocerca volvulus and its relation to ivermectin treatment,” Parasitology, vol. 125, no. 5, pp. 431–444, 2002.
[15]
L. Diawara, M. O. Traoré, A. Badji et al., “Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal,” PLoS Neglected Tropical Diseases, vol. 3, no. 7, article e497, 2009.
[16]
K. A. Lindblade, B. Arana, G. Zea-Flores et al., “Elimination of Onchocercia volvulus transmission in the Santa Rosa focus of Guatemala,” American Journal of Tropical Medicine and Hygiene, vol. 77, no. 2, pp. 334–341, 2007.
[17]
E. Lobos, N. Weiss, M. Karam, H. R. Taylor, E. A. Ottesen, and T. B. Nutman, “An immunogenic Onchocerca volvulus antigen: a specific and early marker of infection,” Science, vol. 251, no. 5001, pp. 1603–1605, 1991.
[18]
E. M. Lipner, N. Dembele, S. Souleymane et al., “Field applicability of a rapid-format anti-Ov-16 antibody test for the assessment of onchocerciasis control measures in regions of endemicity,” Journal of Infectious Diseases, vol. 194, no. 2, pp. 216–221, 2006.
[19]
T. R. Unnasch and S. E. O. Meredith, “The use of degenerate primers in conjunction with strain and species oligonucleotides to classify Onchocerca volvulus,” in Species Diagnostic Protocols: PCR and other Nucleic Acid Methods, J. P. Clapp, Ed., pp. 293–303, Humana Press, Totowa, NJ, USA, 1996.
[20]
P. Fischer, T. Rubaale, S. E. O. Meredith, and D. W. Büttner, “Sensitivity of a polymerase chain reaction-based assay to detect Onchocerca volvulus DNA in skin biopsies,” Parasitology Research, vol. 82, no. 5, pp. 395–401, 1996.
[21]
P. A. Zimmerman, R. H. Guderian, E. Aruajo et al., “Polymerase chain reaction-based diagnosis of Onchocerca volvulus infection: improved detection of patients with onchocerciasis,” Journal of Infectious Diseases, vol. 169, no. 3, pp. 686–689, 1994.
[22]
E. W. Cupp and M. S. Cupp, “Short report: impact of ivermectin community-level treatments on elimination of adult Onchocerca volvulus when individuals receive multiple treatments per year,” American Journal of Tropical Medicine and Hygiene, vol. 73, no. 6, pp. 1159–1161, 2005.
[23]
F. Richards, D. Hopkins, and E. Cupp, “Programmatic goals and approaches to onchocerciasis,” The Lancet, vol. 355, no. 9216, pp. 1663–1664, 2000.
[24]
B. A. Boatin and F. O. Richards, Control of Onchocercerciasis. Advances in Parasitology, vol. 61, Elsevier, 2006.
[25]
Uganda Government Report, “Guidelines for certification of onchocerciasis elimination in Uganda,” Tech. Rep., Uganda Government, Ministry of Health, Kampala, Uganda, 2011.
[26]
WHO Report, “Certification of elimination of human onchocerciasis: criteria and procedures. Following a WHO meeting on “Criteria for Certification of interruption of transmission/elimination of human onchocerciasis”,” Tech. Rep. WHO/CDS/CPE/CEE/2001.18a, World Health Organisation, Geneva, Switzerland, 2001.
[27]
M. Katabarwa, T. Lakwo, P. Habumogisha, F. Richards, and M. Eberhard, “Short report: could neurocysticercosis be the cause of “onchocerciasis-associated” epileptic seizures?” American Journal of Tropical Medicine and Hygiene, vol. 78, no. 3, pp. 400–401, 2008.
[28]
WER, “Meeting of the International Task Force for Disease Eradication, April 2011,” Weekly Epidemiological Record, vol. 86, no. 32, pp. 341–352, 2011.